DEAD box 1 (DDX1) expression predicts for local control and overall survival in early stage, node-negative breast cancer

Cancer

Volumn 118, Issue 4, 2012, Pages 888-898

  Taunk, Neil K ^a   Goyal, Sharad ^a   Wu, Hao ^a   Moran, Meena S ^b   Chen, Sining ^c   Haffty, Bruce G ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

DEAD box 1 (DDX1); early stage breast cancer; ipsilateral breast tumor recurrence (IBTR); molecular markers; radiation therapy

Indexed keywords

DEAD BOX 1 PROTEIN; DEAD BOX PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PARAFFIN; TUMOR MARKER; UNCLASSIFIED DRUG; DEAD BOX PROTEIN 1;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CONTROL; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY; CANCER PATIENT; COHORT ANALYSIS; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DEAD-BOX RNA HELICASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84856796700     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26352     Document Type: Article

References (27)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985; 312: 665-673.
3. Buzdar AU,. Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. Ann Oncol. 2009; 20: 993-999.
4. Harold JB, Jennifer JG,. Adjuvant hormonal therapy for early-stage breast cancer. Surg Oncol Clin N Am. 2010; 19: 639-647.
5. Albain KS, Paik S, van't Veer L,. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast. 2009; 18 (suppl 3): S141-S145.
6. Haffty BG, Goyal S,. Molecular subtyping of early-stage breast cancer: implications for radiation therapy. Int J Radiat Oncol Biol Phys. 2010; 77: 1293-1295.
7. Linder P,. Dead-box proteins: a family affairâactive and passive players in RNP-remodeling. Nucleic Acids Res. 2006; 34: 4168-4180.
8. Tanaka K, Okamoto S, Ishikawa Y, Tamura H, Hara T,. DDX1 is required for testicular tumorigenesis, partially through the transcriptional activation of 12p stem cell genes. Oncogene. 2009; 28: 2142-2151.
9. Rocak S, Linder P,. DEAD-box proteins: the driving forces behind RNA metabolism. Nat Rev Mol Cell Biol. 2004; 5: 232-241.
10. Li L, Monckton EA, Godbout R,. A role for DEAD box 1 at DNA double-strand breaks. Mol Cell Biol. 2008; 28: 6413-6425.
11. Zinsmaier KE, Eberle KK, Buchner E, Walter N, Benzer S,. Paralysis and early death in cysteine string protein mutants of Drosophila. Science. 1994; 263: 977-980.
12. Inoue A, Sawata SY, Taira K, Wadhwa R,. Loss-of-function screening by randomized intracellular antibodies: identification of hnRNP-K as a potential target for metastasis. Proc Natl Acad Sci U S A. 2007; 104: 8983-8988.
13. Godbout R, Packer M, Bie W,. Overexpression of a DEAD box protein (DDX1) in neuroblastoma and retinoblastoma cell lines. J Biol Chem. 1998; 273: 21161-21168.
14. Noguera R, Villamon E, Berbegall A, et al. Gain of MYCN region in a Wilms tumor-derived xenotransplanted cell line. Diagn Mol Pathol. 2010; 19: 33-39.
15. Barr FG, Duan F, Smith LM, et al. Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Genes Chromosomes Cancer. 2009; 48: 661-672.
16. Germain DR, Graham K, Glubrecht DD, Hugh JC, Mackey JR, Godbout R,. DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer. Breast Cancer Res Treat. 2011; 127: 53-63.
17. Balko JM, Arteaga CL,. Dead-box or black-box: is DDX1 a potential biomarker in breast cancer? Breast Cancer Res Treat. 2011; 127: 65-67.
18. Fisher B, Anderson S, Fisher ER, et al. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet. 1991; 338: 327-331.
19. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-752.
20. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003; 100: 10393-10398.
21. Canman CE, Lim D-S, Cimprich KA, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 1998; 281: 1677-1679.
22. Kuroda H, White PS, Sulman EP, et al. Physical mapping of the DDX1 gene to 340 kb 5â of MYCN. Oncogene. 1996; 13: 1561-1565.
23. Amler LC, Schurmann J, Schwab M,. The DDX1 gene maps within 400 kbp 5â to MYCN and is frequently coamplified in human neuroblastoma. Genes Chromosomes Cancer. 1996; 15: 134-137.
24. Weber A, Imisch P, Bergmann E, Christiansen H,. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma. J Clin Oncol. 2004; 22: 2681-2690.
25. Defferrari R, Tonini GP, Conte M, et al. Concomitant DDX1 and MYCN gain in neuroblastoma. Cancer Lett. 2007; 256: 56-63.
26. Godbout R, Li L, Liu RZ, Roy K,. Role of DEAD box 1 in retinoblastoma and neuroblastoma. Future Oncol. 2007; 3: 575-587.
27. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V,. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007; 109: 1721-1728.